NantHealth Added to Nasdaq Biotech Index

Culver City, Calif. – December 13, 2016 — NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it has been selected by NASDAQ for inclusion in the NASDAQ Biotechnology Index® (NASDAQ: NBI).  The...

read more

NantHealth and NantOmics Announce Positive Predictive Value of GPS Cancer Proteomic Analysis of Chemotherapy Biomarker in Lung Cancer to Be Presented at 17th World Conference on Lung Cancer in Vienna

Randomized (TASTE) Trial In Early Stage Non-Small Cell Lung Cancer Trial, Demonstrates That GPS Proteomics Analysis Could Predict Tumor Response To A Platinum/Pemetrexed Chemotherapy Regimen While Standard Immunohistochemistry Test Fails To Do So December 06,...

read more


Media Contact

Jen Hodson
Telephone: 562-397-3639